ADMP · Adamis Pharma

-

Please sign in to comment on ADMP

1 Comment

Admin

4 years ago

Adamis Pharmaceuticals Corporation is currently in a long term uptrend where the price is trading 20.4% above its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.

Adamis Pharmaceuticals Corporation's total revenue sank by 27.1% to $4M since the same quarter in the previous year.

Its net income has dropped by 6.9% to $-7M since the same quarter in the previous year.

Finally, its free cash flow fell by 33.4% to $-6M since the same quarter in the previous year.

Based on the above factors, Adamis Pharmaceuticals Corporation gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US00547W2089
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

PE Ratio	None
Market Cap	7M
Target Price	0.42
Beta	1.28
Dividend Yield	0.0%

ABOUT

Adamis Pharma

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

ADMP · Adamis Pharma

-

Adamis Pharma

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Adamis Pharma using a moving average strategy